The Feasibility of Cardiophrenic Lymphnode Assessment and Removal in Patients Requiring Diaphragmatic Resection During Interval Debulking Surgery for Ovarian Cancer

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30. doi:10.3322/caac.21332.
   PubMed Web of Science ®Google Scholar
• Ataseven B, Chiva LM, Harter P, et al. FIGO stage IV epithelial ovarian, fallopian tube and peritoneal cancer revisited. Gynecol Oncol. 2016;142(3):597–607. doi:10.1016/j.ygyno.2016.06.013.
   PubMed Web of Science ®Google Scholar
• Vergote I, Trope CG, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363(10):943–953. doi:10.1056/NEJMoa0908806.
   PubMed Web of Science ®Google Scholar
• Kehoe S, Hook J, Nankivell M, et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet. 2015;386(9990):249–257. doi:10.1016/S0140-6736(14)62223-6.
   PubMed Web of Science ®Google Scholar
• Vergote I, Coens C, Nankivell M, et al. Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials. Lancet Oncol. 2018;19(12):1680–1687. doi:10.1016/S1470-2045(18)30566-7.
   PubMed Web of Science ®Google Scholar
• Raban O, Peled Y, Krissi H, et al. The significance of paracardiac lymph-node enlargement in patients with newly diagnosed stage IIIC ovarian cancer. Gynecol Oncol. 2015;138(2):259–262. doi:10.1016/j.ygyno.2015.05.007.
   PubMed Web of Science ®Google Scholar
• Fotopoulou C, Hall M, Cruickshank D, et al. British Gynaecological Cancer Society (BGCS) epithelial ovarian/fallopian tube/primary peritoneal cancer guidelines: recommendations for practice. Eur J Obstet Gynecol Reprod Biol. 2017;213:123–139. doi:10.1016/j.ejogrb.2017.04.016.
   PubMed Web of Science ®Google Scholar
• Harter P, Sehouli J, Lorusso D, et al. A randomized trial of lymphadenectomy in patients with advanced ovarian neoplasms. N Engl J Med. 2019;380(9):822–832. doi:10.1056/NEJMoa1808424.
   PubMed Web of Science ®Google Scholar
• Mert I, Kumar A, Sheedy SP, et al. Clinical significance of enlarged cardiophrenic lymph nodes in advanced ovarian cancer: Implications for survival. Gynecol Oncol. 2018;148(1):68–73. doi:10.1016/j.ygyno.2017.10.024.
   PubMed Web of Science ®Google Scholar
• Garbi A, Zanagnolo V, Colombo N, et al. Feasibility of transabdominal cardiophrenic lymphnode dissection in advanced ovarian cancer: initial experience at a tertiary center. Int J Gynecol Cancer. 2017;27(6):1268–1273. doi:10.1097/IGC.0000000000000983.
   PubMed Web of Science ®Google Scholar
• Yoo HJ, Lim MC, Song YJ, et al. Transabdominal cardiophrenic lymph node dissection (CPLND) via incised diaphragm replace conventional video-assisted thoracic surgery for cytoreductive surgery in advanced ovarian cancer. Gynecol Oncol. 2013;129(2):341–345. doi:10.1016/j.ygyno.2012.12.023.
   PubMed Web of Science ®Google Scholar
• Prader S, Vollmar N, Du Bois A, et al. Pattern and impact of metastatic cardiophrenic lymph nodes in advanced epithelial ovarian cancer. Gynecol Oncol. 2019;152(1):76–81. doi:10.1016/j.ygyno.2018.11.001.
   PubMed Web of Science ®Google Scholar
• Tozzi R, Casarin J, Garruto-Campanile R, et al. Morbidity and reversal rate of ileostomy after bowel resection during visceral-peritoneal debulking (VPD) in patients with stage IIIC-IV ovarian cancer. Gynecol Oncol. 2018;148(1):74–78. doi:10.1016/j.ygyno.2017.11.017.
   PubMed Web of Science ®Google Scholar
• Tozzi R, Casarin J, Baysal A, et al. Bowel resection rate but not bowel related morbidity is decreased after interval debulking surgery compared to primary surgery in patents with stage IIIC-IV ovarian cancer. J Gynecol Oncol. 2019;30(2):e25. doi:10.3802/jgo.2019.30.e25.
   PubMed Web of Science ®Google Scholar
• Querleu D, Planchamp F, Chiva L, et al. European society of gynaecologic oncology quality indicators for advanced ovarian cancer surgery. Int J Gynecol Cancer. 2016;26(7):1354–1363. doi:10.1097/IGC.0000000000000767.
   PubMed Web of Science ®Google Scholar
• Salehi S, Mohammar R, Suzuki C, et al. Cardiophrenic lymph node resection in advanced ovarian cancer: surgical outcomes, pre- and postoperative imaging. Acta Oncol. 2018;57(6):820–824. doi:10.1080/0284186X.2017.1409434.
   PubMed Web of Science ®Google Scholar
• Kim TH, Lim MC, Kim SI, et al. Preoperative prediction of cardiophrenic lymph node metastasis in advanced ovarian cancer using computed tomography. Ann Surg Oncol. 2016;23(4):1302–1308. doi:10.1245/s10434-015-5015-0.
   PubMed Web of Science ®Google Scholar
• Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205–213. doi:10.1097/01.sla.0000133083.54934.ae.
   PubMed Web of Science ®Google Scholar
• LaFargue CJ, Bristow RE. Transdiaphragmatic cardiophrenic lymph node resection for stage IV ovarian cancer. Gynecol Oncol. 2015;138(3):762–763. doi:10.1016/j.ygyno.2015.06.002.
   PubMed Web of Science ®Google Scholar
• Nishikimi K, Tate S, Matsuoka A, et al. Metastatic cardiophrenic lymph node resection following full-thickness resection of right diaphragm for advanced ovarian carcinoma. Gynecol Oncol. 2018;150(3):581–583. doi:10.1016/j.ygyno.2018.07.011.
   PubMed Web of Science ®Google Scholar
• Soleymani Majd H, Ferrari F, Manek S, et al. Diaphragmatic peritonectomy vs. full thickness resection with pleurectomy during visceral-peritoneal debulking (VPD) in 100 consecutive patients with stage IIIC-IV ovarian cancer: a surgical-histological analysis. Gynecol Oncol. 2016;140(3):430–435. doi:10.1016/j.ygyno.2015.12.004.
   PubMed Web of Science ®Google Scholar
• Lim MC, Lee HS, Jung DC, et al. Pathological diagnosis and cytoreduction of cardiophrenic lymph node and pleural metastasis in ovarian cancer patients using video-assisted thoracic surgery. Ann Surg Oncol. 2009;16(7):1990–1996. doi:10.1245/s10434-009-0486-5.
   PubMed Web of Science ®Google Scholar
• LaFargue CJ, Sawyer BT, Bristow RE. Short-term morbidity in transdiaphragmatic cardiophrenic lymph node resection for advanced stage gynecologic cancer. Gynecol Oncol Rep. 2016;17:33–37. doi:10.1016/j.gore.2016.05.006.
   PubMed Web of Science ®Google Scholar
• Cowan RA, Tseng J, Murthy V, et al. Feasibility, safety and clinical outcomes of cardiophrenic lymph node resection in advanced ovarian cancer. Gynecol Oncol. 2017;147(2):262–266. doi:10.1016/j.ygyno.2017.09.001.
   PubMed Web of Science ®Google Scholar
• Lopes A, Rangel Costa RL, di Paula R, et al. Cardiophrenic lymph node resection in cytoreduction for primary advanced or recurrent epithelial ovarian carcinoma: a cohort study. Int J Gynecol Cancer. 2019;29(1):188–194. doi:10.1136/ijgc-2018-000073.
   PubMed Web of Science ®Google Scholar
• Prader S, Harter P, Grimm C, et al. Surgical management of cardiophrenic lymph nodes in patients with advanced ovarian cancer. Gynecol Oncol. 2016;141(2):271–275. doi:10.1016/j.ygyno.2016.03.012.
   PubMed Web of Science ®Google Scholar
• Forstner R, Sala E, Kinkel K, et al. ESUR guidelines: ovarian cancer staging and follow-up. Eur Radiol. 2010;20:2773–2780. doi:10.1007/s00330-010-1886-4.
   PubMed Web of Science ®Google Scholar
• Farmakis S, Vejdani K, Muzaffar R, et al. Detection of metastatic disease in cardiophrenic lymph nodes: FDG PET/CT versus contrast-enhanced CT and implications for staging and treatment of disease. Front Oncol. 2013;3:260.
   PubMedGoogle Scholar
• Benedetti Panici P, Di Donato V, Fischetti M, et al. Predictors of postoperative morbidity after cytoreduction for advanced ovarian cancer: analysis and management of complications in upper abdominal surgery. Gynecol Oncol. 2015;137(3):406–411. doi:10.1016/j.ygyno.2015.03.043.
   PubMed Web of Science ®Google Scholar
• Papadia A, Morotti M. Diaphragmatic surgery during cytoreduction for primary or recurrent epithelial ovarian cancer: a review of the literature. Arch Gynecol Obstet. 2013;287(4):733–741. doi:10.1007/s00404-013-2715-1.
   PubMed Web of Science ®Google Scholar
• Aletti GD, Podratz KC, Cliby WA, et al. Stage IV ovarian cancer: disease site-specific rationale for postoperative treatment. Gynecol Oncol. 2009;112(1):22–27. doi:10.1016/j.ygyno.2008.09.010.
   PubMed Web of Science ®Google Scholar
• Morotti M, Becker CM, Menada MV, et al. Targeting tyrosine-kinases in ovarian cancer. Expert Opin Investig Drugs. 2013;22(10):1265–1279. doi:10.1517/13543784.2013.816282.
   PubMed Web of Science ®Google Scholar
• Minig L, Arraras M, Zorrero C, et al. A different surgical approach for cardiophrenic lymph node resection in advanced ovarian cancer. ecancer. 2017;11:780. doi:10.3332/ecancer.2017.780.
   PubMed Web of Science ®Google Scholar
• Reuss A, Du Bois A, Harter P, et al. TRUST: trial of radical upfront surgical therapy in advanced ovarian cancer (ENGOT ov33/AGO-OVAR OP7). Int J Gynecol Cancer. 2019;29(8):1327–1331. doi:10.1136/ijgc-2019-000682.
   PubMed Web of Science ®Google Scholar